WO2015113192A1 - Benzo-lactam compound, synthesis method and application thereof - Google Patents
Benzo-lactam compound, synthesis method and application thereof Download PDFInfo
- Publication number
- WO2015113192A1 WO2015113192A1 PCT/CN2014/071616 CN2014071616W WO2015113192A1 WO 2015113192 A1 WO2015113192 A1 WO 2015113192A1 CN 2014071616 W CN2014071616 W CN 2014071616W WO 2015113192 A1 WO2015113192 A1 WO 2015113192A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- embankment
- group
- formula
- halogen
- Prior art date
Links
- 0 CC(*)*c1ccc(*)cc1N(*)C(C)=O Chemical compound CC(*)*c1ccc(*)cc1N(*)C(C)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Definitions
- the invention relates to the technical field of synthesis and application of benzoheterocyclic compounds, in particular to benzolactam compounds and methods and applications thereof.
- the benzolactam compound itself is a class of compounds having a wide range of bioorganic and pharmaceutical activities or important synthetic intermediates.
- Propionamide is one of the most representative members.
- Propionamide is a herbicide that is absorbed by young shoots and leaves. Soil treatment can effectively prevent annual broadleaf weeds and some grass weeds. Propifluramide is easily degraded in the environment and is safe for later crops.
- a method for the synthesis of propifluramide is disclosed in US Pat. No. 4,640,707, US Pat. No. 4,792, 605, US Pat.
- the key step of the method is to react 6-amino-7-fluoro-2H-M-benzoxazine-3(4H)-one with a halogenated propyne under strong alkali to obtain 4-N-propyl. Alkylation product.
- the propargylation is not chemically selective and produces polypropargylation by-products. This not only wastes expensive intermediates and propargylating agents, but also the purification of impure products leads to an increase in overall process costs.
- JP 5097826A Another method for synthesizing propiflufloxacin is disclosed in JP 5097826A. This method protects the 6 primary amines in 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one with mercapto ketone. This method uses both a large amount of decyl ketone as a protective reagent and a solvent. The reaction was refluxed under reduced pressure for several hours. The resulting protected intermediate is then propargylated to give the 4-N-propyne-6-imine intermediate.
- This method requires not only a large amount of mercapto ketone but also an intermediate of 4-N-propyne-6-imine which is an oily liquid which is difficult to refine and which makes it difficult to synthesize the final high-purity propiflufen product.
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1.
- Said is 15 or propynyl; is p-nitrophenyl or p-chlorophenyl; R 3 is H or methyl; X is 0; Y is H or F; n is 0.
- the compound (I) has the formula:
- X 0, S
- ⁇ is d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- compounds of general formula (III) are:
- X 0, S
- Z is d_ 5 fluorenyl, C 6 -12 12 aryl, d 5 ⁇ amino, d 5 methoxy, d 5 fluorenyl;
- the formula of the compound (IV) is:
- CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
- X 0, S
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1
- the compound (II) described in the step (a) is p-nitrobenzaldehyde, p-chlorobenzaldehyde or hydrazine, hydrazine-dimethylformamide, and the compound (III) is trimethyl orthoformate or triethyl orthoformate.
- the catalyst is a dehydrating agent or an acid
- the dehydrating agent is preferably a molecular sieve, anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride or thionyl chloride
- the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, Phosphoric acid or p-toluenesulfonic acid
- the solvent is an organic solvent, and the organic solvent is preferably toluene, xylene, methanol, ethanol, isopropanol or anthracene, fluorenyl-dimercaptocarboxamide.
- the compound (V) described in the step (b) is chloropropyne, bromopropyne or propyne methanesulfonate, the acid binding agent is an inorganic base or an organic base; and the inorganic base is preferably potassium carbonate or sodium carbonate.
- the organic base is preferably piperidine, pyridine or triethylamine
- the phase transfer catalyst is a quaternary ammonium salt, a quaternary phosphonium salt or a crown ether
- the quaternary ammonium salt Preferably, it is tetrabutylammonium bromide, triethylphenylammonium chloride or tetrabutylammonium hydrogen sulfate
- the quaternary phosphonium salt is preferably hexadecanoyltributylphosphonium bromide or n-butyltri-n-octane
- the guanidine bromide, the crown ether is preferably 18-crown-6.
- R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
- R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
- X 0, S
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1
- n 1-4.
- Step (b) Compound (VII) is reacted with compound (IX), compound (X), compound (XI) or compound (XII) in an organic solvent to obtain a compound ( ⁇ ;>,
- CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
- X 0, S
- Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- ⁇ ⁇ is alkyl, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 6 _ 12 aryl;
- X 0, S
- Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl group embankment, C,
- L 2 is halogen, hydroxy, carbonyloxy
- n 1-4;
- R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
- the catalyst described in the step (a) is an acid or a base, and the acid is preferably one or more of sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid, p-toluenesulfonic acid or zinc chloride; the base is preferably hydrogen.
- the organic solvent is preferably xylene or chlorine.
- the method is not only mild in condition, the process is easy to control, the post-treatment is simple, and the benzolactam compound can be obtained in high yield and high purity.
- the resulting benzolactam compound can be further used for the synthesis of propiflufenic or other benzolactam compounds having a wide variety of bioorganic and pharmaceutical activities.
- the benzolactam compound (VI) has the following formula:
- X 0, S
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1.
- the compound (I) has the formula:
- X is 0, s
- ⁇ is d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- compounds of general formula (III) are:
- X 0, S
- Z is d_ 5 fluorenyl, C 6 -12 12 aryl, d 5 ⁇ amino, d 5 methoxy, d 5 fluorenyl;
- CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
- X 0, S
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1;
- the general formula of the compound (V) is:
- the compound (II) described in the step (a) is p-nitrobenzaldehyde, p-chlorobenzaldehyde or hydrazine, hydrazine-dimethylformamide, and the compound (III) is trimethyl orthoformate or triethyl orthoformate.
- the catalyst is a dehydrating agent or an acid
- the dehydrating agent is preferably a molecular sieve, anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride or thionyl chloride
- the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, Phosphoric acid or p-toluenesulfonic acid
- the solvent is an organic solvent, and the organic solvent is preferably toluene, xylene, methanol, ethanol, isopropanol or anthracene, fluorenyl-dimercaptocarboxamide.
- the compound (V) described in the step (b) is chloropropyne, bromopropyne or propyne methanesulfonate, the acid binding agent is an inorganic base or an organic base; and the inorganic base is preferably potassium carbonate or sodium carbonate.
- the organic base is preferably piperidine, pyridine or triethylamine
- the phase transfer catalyst is a quaternary ammonium salt, a quaternary phosphonium salt or a crown ether
- the quaternary ammonium salt Preferably, it is tetrabutylammonium bromide, triethylphenylammonium chloride or tetrabutylammonium hydrogen sulfate
- the quaternary phosphonium salt is preferably hexadecanoyltributylphosphonium bromide or n-butyltri-n-octane
- the guanidine bromide, the crown ether is preferably 18-crown-6.
- R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
- R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring; X is 0, s;
- ⁇ is 15, d ⁇ 5 ⁇ , halogen, CF 3 , CN;
- n 0 or 1
- n 1-4.
- Step (b) Compound (VII) is reacted with compound (IX), compound (X), compound (XI) or compound (XII) in an organic solvent to obtain a compound ( ⁇ ;>,
- CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
- X 0, S
- Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- X 0, S
- Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
- n 0 or 1
- R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
- L 2 is halogen, hydroxy, carbonyloxy
- n 1-4;
- R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
- the catalyst described in the step (a) is an acid or a base, and the acid is preferably one or more of sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid, p-toluenesulfonic acid or zinc chloride; the base is preferably hydrogen.
- the organic solvent is preferably xylene or chlorine.
Abstract
Disclosed are a benzo-lactam compound, a synthesis method and an application thereof, which comprises the following steps: step (a): compound (I) and compound (II) or compound (III) reacting with an action of a catalyst or without the action of the catalyst and in a condition with a solvent or without the solvent to obtain compound (IV); and step (b): compound (IV) and compound (V) reacting in presence of an acid binding agent and a phase transfer catalyst to obtain component (VI). For a general formula of benzo-lactam compound (VI), see formula I. The method is not only mild in a condition, easy to control in a process, simple in after-treatment, but also capable of obtaining the benzo-lactam compound with a high yield and high purity. The obtained benzo-lactam compound can be further used for synthesizing flumioxazin or other benzo-lactam compounds provided with various wide biological organic and pharmacological activity.
Description
苯并内酰胺化合物及其合成方法和应用 Benzolactam compound and synthesis method and application thereof
技术领域 Technical field
本发明涉及苯并杂环化合物的合成及应用技术领域, 尤其涉及苯并内酰胺化合物及其合 成方法和应用。 The invention relates to the technical field of synthesis and application of benzoheterocyclic compounds, in particular to benzolactam compounds and methods and applications thereof.
背景技术 Background technique
苯并内酰胺化合物本身是一类具有广泛的生物有机和药学活性的化合物或重要的合成中 间体。丙炔氟草胺是其中很具代表性的一员。丙炔氟草胺为由幼芽和叶片吸收的除草剂, 作 土壤处理可有效防除一年生阔叶杂草和部分禾本科杂草。丙炔氟草胺在环境中易降解,对后 茬作物安全。 The benzolactam compound itself is a class of compounds having a wide range of bioorganic and pharmaceutical activities or important synthetic intermediates. Propionamide is one of the most representative members. Propionamide is a herbicide that is absorbed by young shoots and leaves. Soil treatment can effectively prevent annual broadleaf weeds and some grass weeds. Propifluramide is easily degraded in the environment and is safe for later crops.
US 4640707、 US 4792605、 US 4880925和 EP 0170191公开了丙炔氟草胺的合成方法。 该方法关键一步是以 6-氨基 -7-氟 -2H-M-苯并噁嗪 -3(4H)-酮为原料,在强碱作用下与卤代丙 炔反应, 得到 4-N-丙炔化产物。 但是由于底物结构中存在 6-伯胺基团, 炔丙基化时化学选 择性不高, 会产生多炔丙基化副产物。这不仅浪费昂贵的中间体和炔丙基化试剂, 同时不纯 产物的提纯导致整个工艺成本增加。 A method for the synthesis of propifluramide is disclosed in US Pat. No. 4,640,707, US Pat. No. 4,792, 605, US Pat. The key step of the method is to react 6-amino-7-fluoro-2H-M-benzoxazine-3(4H)-one with a halogenated propyne under strong alkali to obtain 4-N-propyl. Alkylation product. However, due to the presence of a 6-primary amine group in the structure of the substrate, the propargylation is not chemically selective and produces polypropargylation by-products. This not only wastes expensive intermediates and propargylating agents, but also the purification of impure products leads to an increase in overall process costs.
JP 5097826A 公开了另一种合成丙炔氟草胺的方法。 该方法用垸基酮对 6-氨基 -7-氟 -2H-1,4-苯并噁嗪 -3(4H)-酮中的 6位伯胺进行保护。 该方法以大量的垸基酮既作保护试剂又 作溶剂。 反应在减压条件下回流反应数小时。 所得的保护中间体再经过炔丙基化得到 4-N- 丙炔 -6-亚胺中间体。 该方法不仅需用大量的垸基酮, 同时得到的 4-N-丙炔 -6-亚胺中间体为 油状液体, 不易精制, 对最终高纯度丙炔氟草胺产物的合成带来难度。 Another method for synthesizing propiflufloxacin is disclosed in JP 5097826A. This method protects the 6 primary amines in 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one with mercapto ketone. This method uses both a large amount of decyl ketone as a protective reagent and a solvent. The reaction was refluxed under reduced pressure for several hours. The resulting protected intermediate is then propargylated to give the 4-N-propyne-6-imine intermediate. This method requires not only a large amount of mercapto ketone but also an intermediate of 4-N-propyne-6-imine which is an oily liquid which is difficult to refine and which makes it difficult to synthesize the final high-purity propiflufen product.
发明内容 Summary of the invention
本发明的目的是克服现有技术的不足, 提供苯并内酰胺化合物及其合成方法和应用。 苯并内酰胺化合物(VI)通
It is an object of the present invention to overcome the deficiencies of the prior art and to provide benzolactam compounds and methods for their synthesis and use. Benzolactam compound (VI)
式中: In the formula:
R H、 d_5垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; RH, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 CM垸基、 CF3、 CN;
X为 0、 s; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, CM alkyl with, CF 3, CN; X is 0, s;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1。 n is 0 or 1.
所述的 为 15或丙炔基; 为对硝基苯基或对氯苯基; R3为 H或甲基; X为 0; Y 为 H或 F; n为 0。 Said is 15 or propynyl; is p-nitrophenyl or p-chlorophenyl; R 3 is H or methyl; X is 0; Y is H or F; n is 0.
苯并内酰胺化合物的制备方法的步骤如下: The steps of the preparation method of the benzolactam compound are as follows:
步骤 (a): 化合物 (I)与化合物 (II)或化合物 (III)在有催化剂或者没有催化剂作用下在有溶剂或 者无溶剂条件下反应得化合物 (IV), Step (a): Compound (I) is reacted with compound (II) or compound (III) in the presence or absence of a catalyst in the presence or absence of a solvent to obtain compound (IV).
步骤 (b): 化合物 (IV)与化合物 (V) 在缚酸剂和相转移催化剂存在下反应得化合物 (VI), 所述的化合物 (I)的通式为:
Step (b): Compound (IV) is reacted with compound (V) in the presence of an acid binding agent and a phase transfer catalyst to obtain compound (VI). The compound (I) has the formula:
式中: In the formula:
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 S; X is 0, S;
丫为 d_5垸基、 卤素、 CF3、 CN; 丫 is d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (II)的通式为: The general formula of compound (II) is:
Ύ ( ) 式中: Ύ ( ) where:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 化合物 (III)的通式为:
It is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; compounds of general formula (III) are:
式中: In the formula:
X为 0、 S; X is 0, S;
为 CM垸基、 ( 6_12芳香基; CM thiol, ( 6 _ 12 aryl;
Z为 d_5垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基;
化合物 (IV)的通式为:
Z is d_ 5 fluorenyl, C 6 -12 12 aryl, d 5垸 amino, d 5 methoxy, d 5 fluorenyl; The formula of the compound (IV) is:
式中: In the formula:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S ; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (V)的通式为: The general formula of the compound (V) is:
(V) (V)
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为卤素, 磺酸酯, 硫酸酯或磷酸酯。 It is a halogen, a sulfonate, a sulfate or a phosphate.
步骤 (a)中所述的化合物 (II)为对硝基苯甲醛、 对氯苯甲醛或 Ν,Ν-二甲基甲酰胺, 化合物 (III)为原甲酸三甲酯或原甲酸三乙酯, 所述的催化剂为脱水剂或酸, 所述的脱水剂优选为分 子筛、 无水硫酸镁、 无水硫酸钠、 无水氯化钙或二氯亚砜; 酸优选为硫酸、 盐酸、 醋酸、 磷 酸或对甲苯磺酸; 所述的溶剂为有机溶剂, 所述的有机溶剂优选为甲苯、 二甲苯、 甲醇、 乙 醇、 异丙醇或 Ν,Ν-二垸基甲酰胺。 The compound (II) described in the step (a) is p-nitrobenzaldehyde, p-chlorobenzaldehyde or hydrazine, hydrazine-dimethylformamide, and the compound (III) is trimethyl orthoformate or triethyl orthoformate. The catalyst is a dehydrating agent or an acid, and the dehydrating agent is preferably a molecular sieve, anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride or thionyl chloride; the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, Phosphoric acid or p-toluenesulfonic acid; the solvent is an organic solvent, and the organic solvent is preferably toluene, xylene, methanol, ethanol, isopropanol or anthracene, fluorenyl-dimercaptocarboxamide.
步骤 (b)中所述的化合物 (V)为氯丙炔、 溴丙炔或丙炔甲磺酸酯, 所述的缚酸剂为无机碱 或有机碱; 无机碱优选为碳酸钾、 碳酸钠、 碳酸氢钠、 氢氧化钠或氢氧化钾; 有机碱优选为 哌啶、 吡啶或三乙胺, 所述的相转移催化剂为季铵盐、 季磷盐或冠醚, 所述的季铵盐优选为 四丁基溴化铵、三乙基苯基氯化铵或四丁基硫酸氢铵,所述的季磷盐优选为十六垸基三丁基 溴化辚或正丁基三正辛基溴化辚, 所述的冠醚优选为 18-冠醚 -6。 The compound (V) described in the step (b) is chloropropyne, bromopropyne or propyne methanesulfonate, the acid binding agent is an inorganic base or an organic base; and the inorganic base is preferably potassium carbonate or sodium carbonate. , sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide; the organic base is preferably piperidine, pyridine or triethylamine, the phase transfer catalyst is a quaternary ammonium salt, a quaternary phosphonium salt or a crown ether, the quaternary ammonium salt Preferably, it is tetrabutylammonium bromide, triethylphenylammonium chloride or tetrabutylammonium hydrogen sulfate, and the quaternary phosphonium salt is preferably hexadecanoyltributylphosphonium bromide or n-butyltri-n-octane The guanidine bromide, the crown ether is preferably 18-crown-6.
苯并内酰胺化合物的应用是用于制备化合物 (VIII), 化合物 (VIII)通式如下: The use of the benzolactam compound is for the preparation of the compound (VIII), and the compound (VIII) has the following formula:
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基; R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
、 R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
m为 1-4。 m is 1-4.
化合物 (VIII)的制备方法的步骤如下: The steps of the preparation method of the compound (VIII) are as follows:
步骤 (a) 化合物 (VI) 在催化剂作用下得化合物 (VII), Step (a) Compound (VI) gives compound (VII) under the action of a catalyst,
步骤 (b) 化合物 (VII)与化合物 (IX)、 化合物 (X)、 化合物 (XI)或化合物 (XII)在有机溶剂中反应 得化合物 (νπι;>, Step (b) Compound (VII) is reacted with compound (IX), compound (X), compound (XI) or compound (XII) in an organic solvent to obtain a compound (νπι;>,
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
式中: In the formula:
!^为^^烷基、 C3_5链烯基、 C3_5炔基、 C6_12芳香基; ! ^^ ^ is alkyl, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 6 _ 12 aryl;
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (IX)的通式如下: The general formula of the compound (IX) is as follows:
o o
R人 (IX) R people ( IX )
式中: In the formula:
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C, R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl group embankment, C,
L2为卤素, 羟基, 羰氧基; L 2 is halogen, hydroxy, carbonyloxy;
式中: In the formula:
m为 1-4; m is 1-4;
式中: In the formula:
, R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环烷基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
步骤 (a)中所述的催化剂为酸或碱, 所述的酸优选为硫酸、 盐酸、 醋酸、 磷酸、 对甲苯 磺酸或氯化锌的一种或多种; 所述的碱优选为氢氧化钠、氢氧化钾、 乙醇胺、水合肼、哌啶、 氨水、 乙胺、 正丙胺或正己胺的一种或多种, 在步骤 (b)中, 所述的有机溶剂优选为二甲苯、 氯苯、 甲苯、 二氯甲垸、 三氯甲垸或醋酸的一种或多种。 The catalyst described in the step (a) is an acid or a base, and the acid is preferably one or more of sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid, p-toluenesulfonic acid or zinc chloride; the base is preferably hydrogen. One or more of sodium oxide, potassium hydroxide, ethanolamine, hydrazine hydrate, piperidine, aqueous ammonia, ethylamine, n-propylamine or n-hexylamine. In the step (b), the organic solvent is preferably xylene or chlorine. One or more of benzene, toluene, methylene chloride, trichloromethane or acetic acid.
本方法不仅条件温和, 过程易于控制, 后处理简单, 而且可以高收率、 高纯度的得到苯 并内酰胺化合物。所得的苯并内酰胺化合物可以进一步用于合成丙炔氟草胺或其它具有各种 广泛生物有机和药学活性的苯并内酰胺化合物。 The method is not only mild in condition, the process is easy to control, the post-treatment is simple, and the benzolactam compound can be obtained in high yield and high purity. The resulting benzolactam compound can be further used for the synthesis of propiflufenic or other benzolactam compounds having a wide variety of bioorganic and pharmaceutical activities.
具体实施方式 detailed description
式中: In the formula:
R H、 d_5垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; RH, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 CM垸基、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, CM alkyl with, CF 3, CN;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1。 n is 0 or 1.
所述的 为 15或丙炔基; 为对硝基苯基或对氯苯基; 为 15或甲基; X为 0; Y 为 H或 F; n为 0。 Said 15 or propynyl; p-nitrophenyl or p-chlorophenyl; 15 or methyl; X is 0; Y is H or F; n is 0.
苯并内酰胺化合物的制备方法的步骤如下: The steps of the preparation method of the benzolactam compound are as follows:
步骤 (a): 化合物 (I)与化合物 (II)或化合物 (III)在有催化剂或者没有催化剂作用下在有溶剂或 者无溶剂条件下反应得化合物 (IV), Step (a): Compound (I) is reacted with compound (II) or compound (III) in the presence or absence of a catalyst in the presence or absence of a solvent to obtain compound (IV).
步骤 (b): 化合物 (IV)与化合物 (V) 在缚酸剂和相转移催化剂存在下反应得化合物 (VI), 所述的化合物 (I)的通式为:
Step (b): Compound (IV) is reacted with compound (V) in the presence of an acid binding agent and a phase transfer catalyst to obtain compound (VI). The compound (I) has the formula:
式中: In the formula:
为 d_5垸基、 卤素、 CF3、 CN; For d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 s; X is 0, s;
丫为 d_5垸基、 卤素、 CF3、 CN; 丫 is d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (II)的通式为: The general formula of compound (II) is:
Ύ ( ) 式中: Ύ ( ) where:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 化合物 (III)的通式为:
It is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; compounds of general formula (III) are:
式中: In the formula:
X为 0、 S; X is 0, S;
为 CM垸基、 ( 6_12芳香基; CM thiol, ( 6 _ 12 aryl;
Z为 d_5垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; Z is d_ 5 fluorenyl, C 6 -12 12 aryl, d 5垸 amino, d 5 methoxy, d 5 fluorenyl;
式中: In the formula:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ;
化合物 (V)的通式为: n is 0 or 1; The general formula of the compound (V) is:
(ν) (ν)
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为卤素, 磺酸酯, 硫酸酯或磷酸酯。 It is a halogen, a sulfonate, a sulfate or a phosphate.
步骤 (a)中所述的化合物 (II)为对硝基苯甲醛、 对氯苯甲醛或 Ν,Ν-二甲基甲酰胺, 化合物 (III)为原甲酸三甲酯或原甲酸三乙酯, 所述的催化剂为脱水剂或酸, 所述的脱水剂优选为分 子筛、 无水硫酸镁、 无水硫酸钠、 无水氯化钙或二氯亚砜; 酸优选为硫酸、 盐酸、 醋酸、 磷 酸或对甲苯磺酸; 所述的溶剂为有机溶剂, 所述的有机溶剂优选为甲苯、 二甲苯、 甲醇、 乙 醇、 异丙醇或 Ν,Ν-二垸基甲酰胺。 The compound (II) described in the step (a) is p-nitrobenzaldehyde, p-chlorobenzaldehyde or hydrazine, hydrazine-dimethylformamide, and the compound (III) is trimethyl orthoformate or triethyl orthoformate. The catalyst is a dehydrating agent or an acid, and the dehydrating agent is preferably a molecular sieve, anhydrous magnesium sulfate, anhydrous sodium sulfate, anhydrous calcium chloride or thionyl chloride; the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, Phosphoric acid or p-toluenesulfonic acid; the solvent is an organic solvent, and the organic solvent is preferably toluene, xylene, methanol, ethanol, isopropanol or anthracene, fluorenyl-dimercaptocarboxamide.
步骤 (b)中所述的化合物 (V)为氯丙炔、 溴丙炔或丙炔甲磺酸酯, 所述的缚酸剂为无机碱 或有机碱; 无机碱优选为碳酸钾、 碳酸钠、 碳酸氢钠、 氢氧化钠或氢氧化钾; 有机碱优选为 哌啶、 吡啶或三乙胺, 所述的相转移催化剂为季铵盐、 季磷盐或冠醚, 所述的季铵盐优选为 四丁基溴化铵、三乙基苯基氯化铵或四丁基硫酸氢铵,所述的季磷盐优选为十六垸基三丁基 溴化辚或正丁基三正辛基溴化辚, 所述的冠醚优选为 18-冠醚 -6。 The compound (V) described in the step (b) is chloropropyne, bromopropyne or propyne methanesulfonate, the acid binding agent is an inorganic base or an organic base; and the inorganic base is preferably potassium carbonate or sodium carbonate. , sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide; the organic base is preferably piperidine, pyridine or triethylamine, the phase transfer catalyst is a quaternary ammonium salt, a quaternary phosphonium salt or a crown ether, the quaternary ammonium salt Preferably, it is tetrabutylammonium bromide, triethylphenylammonium chloride or tetrabutylammonium hydrogen sulfate, and the quaternary phosphonium salt is preferably hexadecanoyltributylphosphonium bromide or n-butyltri-n-octane The guanidine bromide, the crown ether is preferably 18-crown-6.
苯并内酰胺化合物的应用是用于制备化合物 (VIII), 化合物 (VIII)通式如下: The use of the benzolactam compound is for the preparation of the compound (VIII), and the compound (VIII) has the following formula:
式中 Q代表: Where Q represents:
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基; R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
、 R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环;
X为 0、 s; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring; X is 0, s;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
m为 1-4。 m is 1-4.
化合物 (VIII)的制备方法的步骤如下: The steps of the preparation method of the compound (VIII) are as follows:
步骤 (a) 化合物 (VI) 在催化剂作用下得化合物 (VII), Step (a) Compound (VI) gives compound (VII) under the action of a catalyst,
步骤 (b) 化合物 (VII)与化合物 (IX)、 化合物 (X)、 化合物 (XI)或化合物 (XII)在有机溶剂中反应 得化合物 (νπι;>, Step (b) Compound (VII) is reacted with compound (IX), compound (X), compound (XI) or compound (XII) in an organic solvent to obtain a compound (νπι;>,
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (VII)的通式如下: The general formula of the compound (VII) is as follows:
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 C, ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C,
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
式中: In the formula:
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基; R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
L2为卤素, 羟基, 羰氧基; L 2 is halogen, hydroxy, carbonyloxy;
化合物 (X)的通式如下: (X)The general formula of the compound (X) is as follows: (X)
式中: In the formula:
m为 1-4; m is 1-4;
式中: In the formula:
, R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
化合物 (XII)的通式如下: The general formula of the compound (XII) is as follows:
步骤 (a)中所述的催化剂为酸或碱, 所述的酸优选为硫酸、 盐酸、 醋酸、 磷酸、 对甲苯磺 酸或氯化锌的一种或多种; 所述的碱优选为氢氧化钠、 氢氧化钾、 乙醇胺、 水合肼、 哌啶、 氨水、 乙胺、 正丙胺或正己胺的一种或多种, 在步骤 (b)中, 所述的有机溶剂优选为二甲苯、 氯苯、 甲苯、 二氯甲垸、 三氯甲垸或醋酸的一种或多种。 The catalyst described in the step (a) is an acid or a base, and the acid is preferably one or more of sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid, p-toluenesulfonic acid or zinc chloride; the base is preferably hydrogen. One or more of sodium oxide, potassium hydroxide, ethanolamine, hydrazine hydrate, piperidine, aqueous ammonia, ethylamine, n-propylamine or n-hexylamine. In the step (b), the organic solvent is preferably xylene or chlorine. One or more of benzene, toluene, methylene chloride, trichloromethane or acetic acid.
以下所提供的实施例的目的在于说明本发明而不是限定本发明。 The following examples are provided to illustrate the invention and not to limit it.
实施例 1 化合物 0V)的制备 Example 1 Preparation of Compound 0V)
( 1 ) N-6-(7-氟 -3-氧 -3,4-二氢 -2H-苯并 [b][l,4]噁嗪基甲酰亚胺甲酯的合成 (1) Synthesis of N-6-(7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazinylcarbimide methyl ester
在 100ml三口瓶中加入 3.6g 6-氨基 -7-氟 -2H-1,4-苯并噁嗪 -3(4H)-酮, 0.2g对甲苯磺酸和 15ml原甲酸三甲酯, 回流反应并蒸出反应生成的甲醇和过量的原甲酸三甲酯, 冷却至室温,
用水洗, 烘干得到 3.6g固体, 产率为 81%。 Add 3.6 g of 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one, 0.2 g of p-toluenesulfonic acid and 15 ml of trimethyl orthoformate to a 100 ml three-necked flask. And distilling off the methanol formed by the reaction and the excess trimethyl orthoformate, and cooling to room temperature. It was washed with water and dried to give 3.6 g of a solid.
¾ NMR (δ, CDC13): 8.941 (br, IH), 7.824-7.823 (dd, IH), 6.781-6.759 (dd, IH), 6.498-6.480 (dd, IH), 4.600 (s, 2H), 3.898 (s, 3H). MS: [M+H] 225丄 3⁄4 NMR (δ, CDC1 3 ): 8.941 (br, IH), 7.824-7.823 (dd, IH), 6.781-6.759 (dd, IH), 6.498-6.480 (dd, IH), 4.600 (s, 2H), 3.898 (s, 3H). MS: [M+H] 225丄
(2 ) 7-氟 -6-(2-甲基亚丙基胺 )-2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 (2) Synthesis of 7-fluoro-6-(2-methylpropyleneamine)-2H-benzo[b][l,4]oxazine-3(4H)one
在 100ml三口瓶中加入 7.3g 6-氨基 -7-氟 -2H-1,4-苯并噁嗪 -3(4H)-酮和 75ml N,N-二甲基甲 酰胺 (DMF), 搅拌冷却至 -30°C。 滴加 4ml二氯亚砜, 滴加完成后, 升温至 40°C。 反应 1小 时, 冷却至室温, 减压脱去大部分 DMF, 加入 50ml 4M碳酸钾溶液, 过滤, 用水洗涤滤饼, 干燥, 得到 8g固体, 产率为 91%。 Add 7.3 g of 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one and 75 ml of N,N-dimethylformamide (DMF) to a 100 ml three-necked flask, stir and cool. To -30 ° C. 4 ml of thionyl chloride was added dropwise, and after the completion of the dropwise addition, the temperature was raised to 40 °C. After reacting for 1 hour, it was cooled to room temperature, most of the DMF was removed under reduced pressure, 50 ml of 4M potassium carbonate solution was added, filtered, and the filter cake was washed with water and dried to give a solid (yield: 91%).
¾ NMR (δ, CDC13): 9.185 (br, IH), 7.524 (s, IH), 6.723-6.701 (dd, IH), 6.453-6.437 (dd, 1H): 4.561 (s, 2H), 3.019 (s, 6H). MS: [M+H] 238.1. 3⁄4 NMR (δ, CDC1 3 ): 9.185 (br, IH), 7.524 (s, IH), 6.723-6.701 (dd, IH), 6.453-6.437 (dd, 1H) : 4.561 (s, 2H), 3.019 ( s, 6H). MS: [M+H] 238.1.
( 3 ) 6-(4-氯苯亚甲基胺 )-7-氟 -2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 (3) Synthesis of 6-(4-chlorobenzylideneamine)-7-fluoro-2H-benzo[b][l,4]oxazine-3(4H)one
在 250ml三口瓶中加入 11.6g 6-氨基 -7-氟 -2H-1,4-苯并噁嗪 -3(4H)-酮, 10g对氯苯甲醛和 120ml甲苯, 回流并蒸出甲苯, 加入 10ml Ν,Ν-二甲基甲酰胺, 继续回流, 反应 2小时, 停 止加热,搅拌下自然降温至室温,过滤,用乙醇洗涤一次,再用水洗涤,干燥,得固体 15.8g, 产率为 77%。 Add 11.6 g of 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one, 10 g of p-chlorobenzaldehyde and 120 ml of toluene to a 250 ml three-necked flask, reflux and distill off toluene, and add 10 ml hydrazine, hydrazine-dimethylformamide, refluxing, refluxing for 2 hours, heating was stopped, and the mixture was naturally cooled to room temperature under stirring, filtered, washed once with ethanol, washed with water and dried to give a solid, 15.8 g, yield 77 %.
¾ NMR (δ, CDC13): 8.562 (br, IH), 8.494 (s, IH), 7.851 (s, IH), 7.835 (s, IH), 7.464 (s, IH), 7.448 (s, IH), 6.848-6.826 (dd, IH), 6.694-6.679 (dd, IH), 4.645 (s, 2H). MS: [M+H] 305.0 3⁄4 NMR (δ, CDC1 3 ): 8.562 (br, IH), 8.494 (s, IH), 7.851 (s, IH), 7.835 (s, IH), 7.464 (s, IH), 7.448 (s, IH) , 6.848-6.826 (dd, IH), 6.694-6.679 (dd, IH), 4.645 (s, 2H). MS: [M+H] 305.0
(4 ) 6-(4-硝基苯亚甲基胺) -7-氟 -2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 (4) Synthesis of 6-(4-nitrobenzylideneamine)-7-fluoro-2H-benzo[b][l,4]oxazine-3(4H)one
在 250ml三口瓶中加入 21.5g 6-氨基 -7-氟 -2H-1,4-苯并噁嗪 -3(4H)-酮, 17.8g对硝基苯甲 醛和 140ml 甲苯, 回流并蒸出甲苯, 冷却, 过滤, 用乙醇洗涤一次, 再用水洗涤, 干燥, 得到 35.3g固体, 产率为 95%。 21.5 g of 6-amino-7-fluoro-2H-1,4-benzoxazine-3(4H)-one, 17.8 g of p-nitrobenzaldehyde and 140 ml of toluene were added to a 250 ml three-necked flask, and the toluene was refluxed and distilled off. It was cooled, filtered, washed once with ethanol, washed with water and dried to give 35.3 g of solid.
¾ NMR (δ, CDC13): 8.664 (s, IH), 8.344 (s, IH), 8.327 (s, IH), 8.084 (s, IH), 8.068 (s, IH), 7.715 (br, IH), 6.881-6.859 (dd, IH), 6.740-6.725 (dd, IH), 4.663 (s, 2H). MS: [M+H] 316.1 实施例 2 化合物 (VI)的制备 3⁄4 NMR (δ, CDC1 3 ): 8.664 (s, IH), 8.344 (s, IH), 8.327 (s, IH), 8.084 (s, IH), 8.068 (s, IH), 7.715 (br, IH) , 6.881-6.859 (dd, IH), 6.740-6.725 (dd, IH), 4.663 (s, 2H). MS: [M+H] 316.1 Example 2 Preparation of Compound (VI)
( 1 ) 6-(4-氯苯亚甲基胺 )-7-氟 -4-(2-丙炔基) -2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 在 250ml三口瓶中依次加入 12.2g 6-(4-氯苯亚甲基胺 )-7-氟 -2H-苯并 [b][l,4]噁嗪 -3(4H) 酮, 5.5g碳酸钾, O. lg四丁基溴化铵和 100ml DMF,室温下搅拌。加入 4.8 g溴丙炔, 60°C 下反应 7小时, 脱溶, 加水打浆, 过滤, 水洗, 干燥得到 10.7g固体, 产率为 78%。 (1) 6-(4-Chlorobenzylideneamine)-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazin-3(4H)one Synthesis 12.2 g of 6-(4-chlorobenzylideneamine)-7-fluoro-2H-benzo[b][l,4]oxazin-3(4H)one was added in a 250 ml three-necked flask. g potassium carbonate, O. lg tetrabutylammonium bromide and 100 ml DMF, stirred at room temperature. After adding 4.8 g of bromopropyne, the reaction was carried out at 60 ° C for 7 hours, desolvation, watering, filtration, washing with water, and drying to give 10.7 g of a solid, yield 78%.
¾ NMR (δ, CDC13):8.540 (s, IH), 7.878 (s, IH), 7.861 (s, IH), 7.473 (s, IH), 7.455 (s, IH), 7.060-7.045 (dd, IH), 6.868-6.847 (dd, IH), 4.715-4.710 (dd, 2H), 4.666 (s, IH), 2.313-2.303 (t,
1H). MS: [M+H] 343.1 3⁄4 NMR (δ, CDC1 3 ): 8.540 (s, IH), 7.878 (s, IH), 7.861 (s, IH), 7.473 (s, IH), 7.455 (s, IH), 7.060-7.045 (dd, IH), 6.868-6.847 (dd, IH), 4.715-4.710 (dd, 2H), 4.666 (s, IH), 2.313-2.303 (t, 1H). MS: [M+H] 343.1
(2 ) 6-(4-硝基苯亚甲基胺) -7-氟 -4-(2-丙炔基)-2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 在 250ml三口瓶中依次加入 12.6g 6-(4-硝基苯亚甲基胺) -7-氟 -2H-苯并 [b][l,4]噁嗪 -3(4H) 酮, 16.5g碳酸钾, 0.6g四丁基溴化铵和 100ml DMF, -30°C下搅拌。加入 14 g溴丙炔, 50°C 下反应 4小时, 脱溶, 加水打浆, 过滤, 水洗, 干燥得到 13g固体, 产率为 92%。 (2) 6-(4-Nitrobenzylideneamine)-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazin-3(4H) Synthesis of Ketones In a 250 ml three-necked flask, 12.6 g of 6-(4-nitrobenzylideneamine)-7-fluoro-2H-benzo[b][l,4]oxazin-3(4H)one was sequentially added. 16.5 g of potassium carbonate, 0.6 g of tetrabutylammonium bromide and 100 ml of DMF were stirred at -30 °C. 14 g of bromopropyne was added, and the mixture was reacted at 50 ° C for 4 hours, desolvated, water-slurryed, filtered, washed with water, and dried to give 13 g of a solid.
¾ NMR (δ, CDC13): 8.710 (s, 1H), 8.351 (s, 1H), 8.333 (s, 1H), 8.118 (s, 1H), 8.101 (s, 1H), 7.139-7.125 (dd, 1H), 6.897-6.876 (dd, 1H), 4.735-4.731 (dd, 2H), 4.691 (s, 1H), 2.329-2.319 (t, 1H). MS: [M+H] 354.1 3⁄4 NMR (δ, CDC1 3 ): 8.710 (s, 1H), 8.351 (s, 1H), 8.333 (s, 1H), 8.118 (s, 1H), 8.101 (s, 1H), 7.139-7.125 (dd, 1H), 6.897-6.876 (dd, 1H), 4.735-4.731 (dd, 2H), 4.691 (s, 1H), 2.329-2.319 (t, 1H). MS: [M+H] 354.1
实施例 3 化合物 (VII)的合成 Example 3 Synthesis of Compound (VII)
( 1 ) 6-氨基 -7-氟 -4-(2-丙烯基 )-2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 (1) Synthesis of 6-amino-7-fluoro-4-(2-propenyl)-2H-benzo[b][l,4]oxazine-3(4H)one
在 250ml三口瓶中加入 31.9g 6-(4-硝基苯亚甲基胺) -7-氟 -4-(2-丙炔基) -2H-苯并 [b][l,4]噁 嗪 -3(4H)酮, 89g盐酸和 60ml乙醇, 升温至 45°C, 反应 3小时。 脱溶, 用碳酸钠溶液调 pH 值至碱性, 析出大量固体, 过滤, 洗涤至中性, 干燥得到 18.8g固体, 产率为 91%。 Add 31.9g of 6-(4-nitrobenzylideneamine)-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazine to a 250ml three-necked vial -3 (4H) ketone, 89 g of hydrochloric acid and 60 ml of ethanol were heated to 45 ° C and allowed to react for 3 hours. The solution was desolvated, the pH was adjusted to basic with sodium carbonate solution, and a large amount of solid was precipitated, filtered, washed to neutral, and dried to give 18.8 g of solid, yield 91%.
¾ NMR (δ, CDC13): 6.742-6.715 (dd, 1H), 6.661-6.640 (dd, 1H), 4.626-4.620 (dd, 2H), 4.550 (s, 1H), 3.645 (br, 2H), 2.288-2.276 (t, 1H). MS: [M+H] 221.2 3⁄4 NMR (δ, CDC1 3 ): 6.742-6.715 (dd, 1H), 6.661-6.640 (dd, 1H), 4.626-4.620 (dd, 2H), 4.550 (s, 1H), 3.645 (br, 2H), 2.288-2.276 (t, 1H). MS: [M+H] 221.2
(2 ) 6-氨基 -7-氟 -4-(2-丙烯基 )-2H-苯并 [b][l,4]噁嗪 -3(4H)酮的合成 (2) Synthesis of 6-amino-7-fluoro-4-(2-propenyl)-2H-benzo[b][l,4]oxazine-3(4H)one
在 250ml三口瓶中加入 12g 6-(4-氯苯亚甲基胺 )-7-氟 -4-(2-丙炔基) -2H-苯并 [b][l,4]噁嗪 -3(4H)酮, 60ml水和 50ml甲苯, 搅拌均匀后, 0°C下加入 9.8g浓硫酸, 后升温至 80°C, 搅拌反应约 4小时, 分液, 加入碳酸钠溶液调 pH值至碱性, 析出大量固体, 过滤, 水洗干 燥, 得到 6.70 g固体, 收率 88.3%。 Add 12g of 6-(4-chlorobenzylideneamine)-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazine-3 to a 250ml three-necked vial (4H) ketone, 60ml water and 50ml toluene, after stirring evenly, add 9.8g concentrated sulfuric acid at 0 °C, then warm up to 80 ° C, stir the reaction for about 4 hours, separate the liquid, add sodium carbonate solution to adjust the pH to alkali Sex, a large amount of solid was precipitated, filtered, and washed with water to give 6.70 g of solid, yield 88.3%.
实施例 4化合物 (VIII)的合成 Example 4 Synthesis of Compound (VIII)
( 1 ) 2-(7-氟 -3-氧 -4-(2-丙炔基 )-3,4-二氢 -2H-苯并 [b][l,4]噁嗪 -6-基) -4,5,6,7-四氢邻苯二 甲酰亚胺的合成 (1) 2-(7-Fluoro-3-oxo-4-(2-propynyl)-3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl) Synthesis of -4,5,6,7-tetrahydrophthalimide
在 100ml三口瓶中加入 6g 6-氨基 -7-氟 -4-(2-丙炔基 )-2H-苯并 [b][l,4]噁嗪 -3(4H)酮, 4.1g 四氢苯酐和 35ml醋酸, 升温回流反应。 反应结束后, 脱溶, 加甲醇打浆, 过滤, 干燥得到 7g固体, 产率为 72%。 6g of 6-amino-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazin-3(4H)one, 4.1g tetrahydrogen was added to a 100ml three-necked vial Phthalic anhydride and 35 ml of acetic acid were heated to reflux. After completion of the reaction, the solution was desolvated, methanol-slurried, filtered, and dried to give 7 g of solid, yield 72%.
¾ NMR (δ, CDC13): 7.056-7.040 (dd, 1H), 6.912-6.888 (dd, 1H), 4.678 (s, 2H), 4.667-4.660 (dd, 2H), 2.540-2.435 (m, 4H), 2.301-2.294 (dd, 1H), 1.845-1.839 (m, 4H). MS: [M+H] 355.1 3⁄4 NMR (δ, CDC1 3 ): 7.056-7.040 (dd, 1H), 6.912-6.888 (dd, 1H), 4.678 (s, 2H), 4.667-4.660 (dd, 2H), 2.540-2.435 (m, 4H ), 2.301-2.294 (dd, 1H), 1.845-1.839 (m, 4H). MS: [M+H] 355.1
( 2 ) 2-(7-氟 -3-氧 -4-(2-丙炔基 )-3,4-二氢 -2H-苯并 [b][l,4]噁嗪 -6-基) -4,5,6,7-四氢邻苯二 甲酰亚胺的合成
在 100ml 三口瓶中加入 4.4g 6-氨基 -7-氟 -4-(2-丙炔基 )-2H-苯并 [b][l,4]噁嗪 -3(4H)酮和(2) 2-(7-Fluoro-3-oxo-4-(2-propynyl)-3,4-dihydro-2H-benzo[b][l,4]oxazin-6-yl) Synthesis of -4,5,6,7-tetrahydrophthalimide Add 4.4 g of 6-amino-7-fluoro-4-(2-propynyl)-2H-benzo[b][l,4]oxazin-3(4H)one to a 100 ml three-necked flask and
35ml醋酸, 0°C下加入 12.2g四氢苯酐, 升温回流反应。 反应结束后, 脱溶, 加甲醇打浆, 过滤, 干燥得到 5.7g固体, 产率为 80%。
35 ml of acetic acid, 12.2 g of tetrahydrophthalic anhydride was added at 0 ° C, and the reaction was refluxed under heating. After completion of the reaction, the solution was desolvated, methanol-boiled, filtered, and dried to give 5.7 g of a solid.
Claims
式中: In the formula:
R H、 d_5垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; RH, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 CM垸基、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, CM alkyl with, CF 3, CN;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1。 n is 0 or 1.
2. 如权利要求 1所述的苯并内酰胺化合物, 其特征在于, 所述的 1^为 H或丙炔基; 为 对硝基苯基或对氯苯基; R3为 H或甲基; X为 0; Y为 H或 F; n为 0。 The benzolactam compound according to claim 1, wherein the compound is H or propynyl; is p-nitrophenyl or p-chlorophenyl; R 3 is H or methyl ; X is 0; Y is H or F ; n is 0.
3. 一种如权利要求 1所述苯并内酰胺化合物 (VI)的制备方法, 其特征在于它的步骤如下: 步骤 (a): 化合物 (I)与化合物 (II)或化合物 (III)在有催化剂或者没有催化剂作用下在有溶剂或 者无溶剂条件下反应得化合物 (IV), A process for producing a benzolactam compound (VI) according to claim 1, wherein the steps are as follows: Step (a): Compound (I) and compound (II) or compound (III) Compound (IV) is obtained by reacting with or without a catalyst in the presence or absence of a solvent,
步骤 (b): 化合物 (IV)与化合物 (V) 在缚酸剂和相转移催化剂存在下反应得化合物 (VI), 所述的化合物 (I)的通式为:
Step (b): Compound (IV) is reacted with compound (V) in the presence of an acid binding agent and a phase transfer catalyst to obtain compound (VI). The compound (I) has the formula:
式中: In the formula:
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 S; X is 0, S;
丫为 d_5垸基、 卤素、 CF3、 CN; 丫 is d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (II)的通式为:
Ύ (n) 式中: The formula of the compound (II) is: Ύ ( n ) where:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 化合物 (III)的通式为:
It is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 amino embankment, d_ 5 embankment group, d_ 5 embankment mercapto; compounds of general formula (III) are:
式中: In the formula:
X为 0、 S; X is 0, S;
为 CM垸基、 ( 6_12芳香基; CM thiol, ( 6 _ 12 aryl;
Z为 d_5垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; Z is d_ 5 fluorenyl, C 6 -12 12 aryl, d 5垸 amino, d 5 methoxy, d 5 fluorenyl;
式中: In the formula:
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (V)的通式为: The general formula of the compound (V) is:
(V) 式中: (V) where:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为卤素, 磺酸酯, 硫酸酯或磷酸酯。 It is a halogen, a sulfonate, a sulfate or a phosphate.
4. 如权利要求 3所述一种制备苯并内酰胺化合物 (VI) 的方法, 其特征在于步骤 (a)中所述的 化合物 (II)为对硝基苯甲醛、 对氯苯甲醛或 Ν,Ν-二甲基甲酰胺, 化合物 (III)为原甲酸三甲酯 或原甲酸三乙酯, 所述的催化剂为脱水剂或酸, 所述的脱水剂优选为分子筛、 无水硫酸镁、 无水硫酸钠、 无水氯化钙或二氯亚砜; 酸优选为硫酸、 盐酸、 醋酸、 磷酸或对甲苯磺酸; 所
述的溶剂为有机溶剂, 所述的有机溶剂优选为甲苯、 二甲苯、 甲醇、 乙醇、 异丙醇或 Ν,Ν- 二垸基甲酰胺。 The method for producing a benzolactam compound (VI) according to claim 3, wherein the compound (II) in the step (a) is p-nitrobenzaldehyde, p-chlorobenzaldehyde or hydrazine. , Ν-dimethylformamide, the compound (III) is trimethyl orthoformate or triethyl orthoformate, the catalyst is a dehydrating agent or an acid, and the dehydrating agent is preferably a molecular sieve, anhydrous magnesium sulfate, Anhydrous sodium sulfate, anhydrous calcium chloride or thionyl chloride; the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid or p-toluenesulfonic acid; The solvent is an organic solvent, and the organic solvent is preferably toluene, xylene, methanol, ethanol, isopropanol or hydrazine, fluorenyl-dimercaptocarboxamide.
5. 如权利要求 3 所述一种制备苯并内酰胺化合物 (VI)的方法, 其特征在于步骤 (b)中所述的 化合物 (V)为氯丙炔、 溴丙炔或丙炔甲磺酸酯, 所述的缚酸剂为无机碱或有机碱; 无机碱优 选为碳酸钾、碳酸钠、碳酸氢钠、氢氧化钠或氢氧化钾; 有机碱优选为哌啶、吡啶或三乙胺, 所述的相转移催化剂为季铵盐、季磷盐或冠醚, 所述的季铵盐优选为四丁基溴化铵、三乙基 苯基氯化铵或四丁基硫酸氢铵,所述的季磷盐优选为十六垸基三丁基溴化辚或正丁基三正辛 基溴化辚, 所述的冠醚优选为 18-冠醚 -6。 The method for producing a benzolactam compound (VI) according to claim 3, wherein the compound (V) in the step (b) is chloropropyne, bromopropyne or propyne methane. The acid ester, the acid binding agent is an inorganic base or an organic base; the inorganic base is preferably potassium carbonate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide; the organic base is preferably piperidine, pyridine or triethylamine. The phase transfer catalyst is a quaternary ammonium salt, a quaternary phosphonium salt or a crown ether, and the quaternary ammonium salt is preferably tetrabutylammonium bromide, triethylphenylammonium chloride or tetrabutylammonium hydrogen sulfate. The quaternary phosphonium salt is preferably hexadecanyl tributylphosphonium bromide or n-butyl tri-n-octylphosphonium bromide, and the crown ether is preferably 18-crown ether-6.
6. 一种如权利要求 1所述苯并内酰胺化合物的应用, 其特征在于用于制备化合物 (VIII), 化 合物 (VIII)通式如下: 6. Use of a benzolactam compound according to claim 1, characterized in that it is used for the preparation of compound (VIII), and the compound (VIII) has the following formula:
式中 Q代表: Where Q represents:
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基; R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
、 R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
X为 0、 S; X is 0, S;
丫为15、 d_5垸基、 卤素、 CF3、 CN; 丫 is 15, d 垸5垸, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
m为 1-4。 m is 1-4.
7. 如权利要求 6所述苯并内酰胺化合物的应用, 其特征在于化合物 (VIII)的制备方法的步骤
步骤 (a) 化合物 (VI) 在催化剂作用下得化合物 (VII), 7. Use of a benzolactam compound according to claim 6, characterized by the step of the preparation method of the compound (VIII) Step (a) Compound (VI) gives compound (VII) under the action of a catalyst,
步骤 (b) 化合物 (VII)与化合物 (IX)、 化合物 (X)、 化合物 (XI)或化合物 (XII)在有机溶剂中反应 得化合物 (νπι;>, Step (b) Compound (VII) is reacted with compound (IX), compound (X), compound (XI) or compound (XII) in an organic solvent to obtain a compound (νπι;>,
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 ( 6_12芳香基; ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl group, (6 _ 12 aryl;
为 CM垸基、 C3_7环垸基、 C6_12芳香基、 d_5垸氨基、 d_5垸氧基、 d_5垸巯基; 为15、 d_5垸基、 卤素、 CF3、 CN; Is CM alkyl with, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group, d_ 5 embankment amino, d_ 5 embankment group, d_ 5 embankment mercapto; to 15, d_ 5 embankment, halogen, CF 3, CN ;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
化合物 (VII)的通式如下: The general formula of the compound (VII) is as follows:
式中: In the formula:
!^为。^垸基、 C3_5链烯基、 C3_5炔基、 C, ! ^为为. ^ Embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C,
为15、 d_5垸基、 卤素、 CF3、 CN; Is 15, d_ 5 fluorenyl, halogen, CF 3 , CN;
X为 0、 S; X is 0, S;
Y为 H, d_5垸基, 卤素, CF3, CN; Y is H, d_ 5 fluorenyl, halogen, CF 3 , CN;
n为 0或 1 ; n is 0 or 1;
式中: In the formula:
R7为 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基; R 7 is H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl;
L2为卤素, 羟基, 羰氧基;
化合物 (X)的通式如下:
L 2 is halogen, hydroxy, carbonyloxy; The general formula of the compound (X) is as follows:
式中: In the formula:
m为 1-4; m is 1-4;
式中: In the formula:
, R9选自 H, d_5垸基、 C3_5链烯基、 C3_5炔基、 C3_7环垸基、 C6_12芳香基或者合并 一起成为三亚甲基, 四亚甲基或五亚甲基环; , R 9 is selected from H, d_ 5 embankment group, C 3 _ 5 alkenyl, C 3 _ 5 alkynyl, C 3 _ 7 cycloalkyl embankment group, C 6 _ 12 aryl group or combined together as trimethylene, tetramethylene, Methylene or pentamethylene ring;
化合物 (XII)的通式如下: The general formula of the compound (XII) is as follows:
8. 如权利要求 7所述苯并内酰胺化合物的应用, 其特征在于步骤 (a)中所述的催化剂为酸或 碱, 所述的酸优选为硫酸、 盐酸、 醋酸、 磷酸、 对甲苯磺酸或氯化锌的一种或多种; 所述的 碱优选为氢氧化钠、 氢氧化钾、 乙醇胺、 水合肼、 哌啶、 氨水、 乙胺、 正丙胺或正己胺的一 种或多种, 在步骤 (b)中, 所述的有机溶剂优选为二甲苯、 氯苯、 甲苯、 二氯甲垸、 三氯甲 垸或醋酸的一种或多种。
The use of the benzolactam compound according to claim 7, wherein the catalyst in the step (a) is an acid or a base, and the acid is preferably sulfuric acid, hydrochloric acid, acetic acid, phosphoric acid or p-toluene. One or more of an acid or zinc chloride; the base is preferably one or more of sodium hydroxide, potassium hydroxide, ethanolamine, hydrazine hydrate, piperidine, aqueous ammonia, ethylamine, n-propylamine or n-hexylamine. In the step (b), the organic solvent is preferably one or more of xylene, chlorobenzene, toluene, methylene chloride, trichloromethane or acetic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/071616 WO2015113192A1 (en) | 2014-01-28 | 2014-01-28 | Benzo-lactam compound, synthesis method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/071616 WO2015113192A1 (en) | 2014-01-28 | 2014-01-28 | Benzo-lactam compound, synthesis method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015113192A1 true WO2015113192A1 (en) | 2015-08-06 |
Family
ID=53756089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/071616 WO2015113192A1 (en) | 2014-01-28 | 2014-01-28 | Benzo-lactam compound, synthesis method and application thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015113192A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105399699A (en) * | 2015-11-02 | 2016-03-16 | 迈克斯(如东)化工有限公司 | Preparation method and application of N-propinyl benzolactam compound |
RU2652135C2 (en) * | 2013-11-08 | 2018-04-25 | Сумитомо Кемикал Компани, Лимитед | Succinimide compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292720A (en) * | 1998-04-13 | 1999-10-26 | Nissan Chem Ind Ltd | Herbicide containing condensed imidazolinone derivative |
WO2009126527A1 (en) * | 2008-04-07 | 2009-10-15 | Cv Therapeutics, Inc. | 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors |
-
2014
- 2014-01-28 WO PCT/CN2014/071616 patent/WO2015113192A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292720A (en) * | 1998-04-13 | 1999-10-26 | Nissan Chem Ind Ltd | Herbicide containing condensed imidazolinone derivative |
WO2009126527A1 (en) * | 2008-04-07 | 2009-10-15 | Cv Therapeutics, Inc. | 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2652135C2 (en) * | 2013-11-08 | 2018-04-25 | Сумитомо Кемикал Компани, Лимитед | Succinimide compound |
CN105399699A (en) * | 2015-11-02 | 2016-03-16 | 迈克斯(如东)化工有限公司 | Preparation method and application of N-propinyl benzolactam compound |
CN105399699B (en) * | 2015-11-02 | 2018-04-03 | 迈克斯(如东)化工有限公司 | A kind of preparation method and applications of N propinyls benzolactam compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6181168B2 (en) | Process for the preparation of certain 2- (pyridin-3-yl) thiazoles | |
JP6181166B2 (en) | Process for the preparation of certain 2- (pyridin-3-yl) thiazoles | |
US8314249B2 (en) | Process for the preparation of [4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-thiazolo-2-yl]-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl | |
JP2021066723A (en) | Preparation method for m-diamide compounds | |
CN103788013A (en) | Synthetic method of 2-aryl benzothiazole compounds | |
WO2015113192A1 (en) | Benzo-lactam compound, synthesis method and application thereof | |
CN103059010B (en) | Isosorbide-5-Nitrae-benzoxazinone-1,2,3-triazole compound with anti-mycotic activity and preparation method thereof | |
ES2759795T3 (en) | New method for the preparation of a thienopyrimidine compound and intermediates used therein | |
JP2008169162A (en) | Method for producing methylene disulfonate compound | |
CN103755658A (en) | Benzene and lactam compound and synthetic method and application thereof | |
AU2006240772B2 (en) | Method for producing nicotinic acid derivative or salt thereof | |
CN103965203B (en) | Imidazo-[1,2-c]-quinazolin-3(2H)-one fused-heterocycle compounds and preparation method thereof | |
KR101457453B1 (en) | Process for preparing gefitinib and an intermediate used for preparing thereof | |
JP6930923B2 (en) | (E)-Improved process for preparing -(5,6-dihydro-1,4,2-dioxazine-3-yl) (2-hydroxyphenyl) metanone O-methyloxime | |
JP4675234B2 (en) | Intermediate for producing optically active quinolonecarboxylic acid derivative and process for producing the same | |
JP2008169161A (en) | Method for producing methylene disulfonate compound | |
TWI542578B (en) | Preparation of Benzyl Nicotinic Acid Benzyl Ester Derivatives | |
JP4194984B2 (en) | Phenylnaphthylimidazole compound | |
CN102924375B (en) | Talnetant intermediate, preparation method and applications thereof | |
TW201920076A (en) | Method for preparing substituted 4-aminoindane derivatives | |
JP5148836B2 (en) | Process for producing nicotinic acid derivative or salt thereof | |
CN103880765A (en) | Chemical synthesis method of 3-isoxazolyl benzyl acetate | |
JPH0348905B2 (en) | ||
CN102702099A (en) | Preparation method of (S)-3-hydroxy-2-phenyl-N-(1-phenylpropyl) quinoline-4-formamide | |
JPWO2002064554A1 (en) | Cyanothioacetamide derivatives and production method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14881385 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14881385 Country of ref document: EP Kind code of ref document: A1 |